Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
1.880
+0.010 (0.53%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Larimar Therapeutics Stock Forecast
LRMR's stock price has decreased by -72.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Larimar Therapeutics stock have an average target of 19, with a low estimate of 10 and a high estimate of 26. The average target predicts an increase of 910.64% from the current stock price of 1.88.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Larimar Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +1,282.98% | Mar 25, 2025 |
| Baird | Baird | Buy Maintains $13 → $10 | Buy | Maintains | $13 → $10 | +431.91% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +751.06% | Mar 25, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +857.45% | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +697.87% | Jan 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 433.59M
Revenue Next Year
n/a
EPS This Year
-1.82
from -1.32
EPS Next Year
-2.04
from -1.82
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 45.9M | 169.1M | ||
| Avg | n/a | 8.3M | 77.5M | ||
| Low | n/a | n/a | 7.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,941.2% | ||
| Avg | - | - | 836.2% | ||
| Low | - | - | -7.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.32 | -0.95 | -0.21 | ||
| Avg | -1.82 | -2.04 | -1.62 | ||
| Low | -2.46 | -2.78 | -2.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.